Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexeo Therapeutics (LXEO) Accumulated Expenses (2022 - 2026)

Lexeo Therapeutics' Accumulated Expenses history spans 2 years, with the latest figure at $10.8 million for Q4 2023.

  • On a quarterly basis, Accumulated Expenses rose 68.85% to $10.8 million in Q4 2023 year-over-year; TTM through Dec 2023 was $10.8 million, a 68.85% increase, with the full-year FY2023 number at $10.8 million, up 68.85% from a year prior.
  • Accumulated Expenses hit $10.8 million in Q4 2023 for Lexeo Therapeutics, up from $1.8 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for LXEO hit a ceiling of $10.8 million in Q4 2023 and a floor of $1.8 million in Q3 2023.